Irinotecan hydrochloride

Irinotecan hydrochloride (CPT-11), a camptothecin derivative, is a prodrug that is converted to the active compound SN-38, which in turn inhibits topoisomerase I. CPT-11 was evaluated in a phase II study involving 13 patients (3 acute and 10 lymphoma) with relapsed or refractory ATL.111 Median age was 63 years (range 44-78 years). The OR rate was 38.5% (CR 7.7%; PR 30.8%) with a median response duration of 31 days. All responders had lymphoma subtype. Grade 3 or 4 toxicities included leukopenia (66.7%), thrombocytopenia (41.7%), anemia (33.3%), and diarrhea (46.2%). One treatment-related death occurred.

0 0

Post a comment